Astellas Venture Management

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Avilar Therapeutics is a biopharmaceutical company dedicated to the discovery and development of extracellular protein degraders, which represent an innovative approach to targeted protein degradation. The company has created an integrated discovery platform that extends the concept of protein degradation beyond intracellular proteins. Avilar’s novel degraders are designed to bind to disease-causing proteins in circulation and shuttle them to the hepatocyte endolysosome for degradation. This mechanism aims to facilitate the treatment of serious diseases by removing unwanted proteins from the body, thereby offering potential therapeutic benefits in various medical conditions.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

Casma Therapeutics, Inc. specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy and lysosomal flux. By focusing on enhancing autophagy, the company aims to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing the progression of various diseases. Its research targets several serious medical conditions, including lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration. Founded in 2017 and based in Cambridge, Massachusetts, Casma Therapeutics is dedicated to creating effective treatment options that meet significant unmet medical needs in the field of drug discovery and development.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.

Carbon Biosciences focuses on developing genetic medicines to address serious diseases. The company utilizes a proprietary platform that employs novel parvoviruses, which are designed to target specific tissues and carry larger therapeutic cargo. This approach minimizes the risk of neutralizing immunity and allows for repeat dosing, making it particularly effective for conditions such as cystic fibrosis, where targeting lung and upper airway tissues is crucial. By leveraging industrial-scale viral production platforms, Carbon Biosciences aims to extend the reach of gene therapies, offering innovative solutions for researchers and patients alike.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Toregem BioPharma, a startup originating from Kyoto University, is focused on developing therapeutic agents aimed at dental regeneration. Headquartered in Kyoto, Japan, the company specializes in treatments for congenital adentia and other dental issues. Its primary product is a tooth regeneration therapeutic agent that utilizes patients' own tissues to regenerate lost teeth. This innovative approach aims to provide solutions for individuals who have lost teeth due to decay or periodontal disease, ultimately promoting better oral health and improving quality of life.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.

Keyhole Therapeutics is a discovery stage drug company specializing in immunotherapies for cancer and autoimmune diseases. Keyhole's first program, a small molecule inhibitor of exosome release being investigated for promotion of immune-driven tumor destruction in cancer patients resistant to current immune checkpoint inhibitors, is at the hit-to-lead stage. Future programs will include additional inhibitors of exosome release, and novel exosome-related therapeutic opportunities for cellular cancer vaccines and for targeted suppression of autoreactive T cells. Keyhole Therapeutics is seeking bold, accomplished, and innovative scientists to join them in pioneering the next wave of immunotherapeutics.

Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

Fukushima SiC Applied Engineering is a manufacturer of silicon carbide semiconductor devices for the medical and industrial fields. Using this SiC device, Fukushima SiC Applied Engineering Research Institute has the technology to design and manufacture circuits that handle high voltages and currents ranging from 10 KV to several hundred kV and 10 A to 1000 A. The company commercializes a circuit that uses a series resonance circuit to achieve high output and stability.

Trishula Therapeutics is a privately held company focused on developing innovative cancer immunotherapies, specifically TTX-030, a first-in-class anti-CD39 antibody created in collaboration with AbbVie. TTX-030 works by inhibiting the enzyme CD39, which is responsible for converting ATP to AMP, thereby preventing the formation of immune-suppressive extracellular adenosine in the tumor microenvironment. This mechanism helps sustain high levels of immune-activating extracellular ATP, which is crucial for stimulating dendritic and myeloid-derived cells essential for both innate and adaptive immune responses. Currently, TTX-030 is being evaluated in phase 1/1b clinical trials as a standalone treatment and in combination with an anti-PD-1 agent and standard chemotherapy for adults with advanced cancer.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Redona Therapeutics focuses on developing RNA-based therapies aimed at treating cancer and various human diseases. The company researches short non-coding RNAs that inhibit gene expression by suppressing mRNA translation and promoting mRNA decay. By targeting RNA modulating proteins with small molecules, Redona Therapeutics seeks to adjust the expression levels of oncogenes and other significant proteins involved in disease processes. This innovative approach enables health professionals to specifically target microRNAs that play critical roles in cancer initiation, progression, and metastasis, offering potential new avenues for therapeutic intervention.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

J-BEAM develops, manufactures, and sells products that apply silicon carbide semiconductors. Utilizing SiC semiconductor technology, it has developed a treatment device for boron neutron capture therapy (BNCT) and is working toward its practical application.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

Trieza Therapeutics is a biotechnology company focused on developing immunomodulatory oncolytic viruses for cancer treatment. Originating as a spin-out from Potenza Therapeutics, Trieza is building a portfolio of pre-clinical candidates designed to stimulate anti-tumor immune responses. The company's approach combines effective tumor-selective destruction with the rapid, transient expression of engineered transgenes that encode immunomodulatory agents. This innovative strategy aims to enhance the efficacy of immune-stimulants, checkpoint inhibitors, and ligands for co-inhibitory receptors, ultimately improving treatment outcomes for cancer patients.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Raze Therapeutics focuses on discovering and developing innovative oncology therapeutics that target essential metabolic pathways crucial for cancer growth and survival. The company is advancing a pipeline of treatments based on novel biological insights into how cancer cells reprogram their metabolism to support tumor development. By selectively targeting one-carbon metabolism through a proprietary platform, Raze aims to provide patients with quicker access to treatment and improve the chances of successful outcomes.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative peptides and monoclonal antibodies aimed at addressing acute tissue-damaging inflammation. The company's therapeutics target conditions such as myocardial infarction, second-degree burns, vascular injury, and reperfusion injury in transplant patients. By focusing on an innate IgM-mediated autoimmune pathway, DecImmune Therapeutics seeks to enhance treatment options for various inflammatory diseases, including diabetic nephropathy and renal ischemia. Founded in 2001 and originally known as Natural Antibodies, Inc., the company rebranded in 2004 to reflect its commitment to advancing therapeutic solutions in the field of inflammation and autoimmunity.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments to enhance the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K), which is approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma after previous therapies. Additionally, Verastem is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, currently being studied in combination with immunotherapies for various cancers, including pancreatic and non-small cell lung cancer. The company focuses on targeting critical signaling pathways in cancer to inhibit tumor growth and promote cell death. Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited, and is headquartered in Needham, Massachusetts.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

PanOptica, Inc. is a biopharmaceutical company based in Mount Arlington, New Jersey, focused on developing innovative treatments for sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009, the company is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. By seeking to license and develop novel therapeutics, PanOptica aims to address the limitations of existing treatments and improve patient outcomes in ophthalmology. The company serves pharmaceutical firms and is committed to enhancing the quality of life for patients experiencing vision loss due to these debilitating conditions.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative peptides and monoclonal antibodies aimed at addressing acute tissue-damaging inflammation. The company's therapeutics target conditions such as myocardial infarction, second-degree burns, vascular injury, and reperfusion injury in transplant patients. By focusing on an innate IgM-mediated autoimmune pathway, DecImmune Therapeutics seeks to enhance treatment options for various inflammatory diseases, including diabetic nephropathy and renal ischemia. Founded in 2001 and originally known as Natural Antibodies, Inc., the company rebranded in 2004 to reflect its commitment to advancing therapeutic solutions in the field of inflammation and autoimmunity.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Intradigm is a private biotechnology company focused on developing systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, with an initial emphasis on oncology. The company leverages its expertise in drug development and delivery to create a proprietary RNAi platform, which includes unique RNAi Nanoplex delivery technology. This technology enables the targeted delivery of RNAi therapeutics to specific tissues through systemic administration. Intradigm's portfolio encompasses RNAi molecules, biodegradable polycationic polymers for therapeutic delivery, and a range of siRNA sequences targeting various oncology and other disease-related applications.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Inimex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of Innate Defense Regulators (IDRs). These innovative drugs are designed to selectively modulate the body's innate immune defenses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, reduce tissue damage, and mitigate bacterial infections. Inimex's IDR products target a range of medical conditions, including infections and tissue injury-related ailments such as ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is dedicated to advancing its unique therapies to improve patient outcomes.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to drug discovery and development, specializing in next-generation ion channel modulators. The company aims to create a robust pipeline of first-in-class therapeutics, primarily targeting pain management and urinary bladder disorders. Utilizing proprietary proteomics technology, Lectus Therapeutics focuses on developing innovative treatments for various conditions, including angina, asthma, and epilepsy, alongside its core areas of interest. Through its commitment to advancing ion channel therapeutics, the company seeks to address unmet medical needs in the pharmaceutical landscape.